British regulator cites 41 more blood clot reports following AstraZeneca shots

Business

Reuters 29 April, 2021 - 05:11pm 31 views

Is Microsoft stock a buy?

The post-earnings decline in Microsoft's stock is a perfect buying opportunity, CNBC's Jim Cramer said Wednesday. Shares of the tech giant were trading lower by more than 3% in late-morning trading as investors digested the company's fiscal third-quarter results. CNBCCramer says Microsoft is 'the stock to buy' on its post-earnings dip

Britain's medicine regulator on Thursday said there had been a further 41 reports of rare blood clots after doses of AstraZeneca's COVID-19 vaccine, but that the benefits of the shot continued to outweigh the risks for the majority of people.

In a weekly update on side effects from COVID-19 vaccines, the Medicines and Healthcare products Regulatory Agency (MHRA) said there were a total of 209 clots with low platelet counts following vaccination with AstraZeneca's shot, compared to a total of 168 reported last week.

There has been scrutiny of the AstraZeneca vaccine on the issue of the very rare clots, with a higher incidence in younger people. Some countries, including Britain, have recommended that only people over a certain age get the shot.

There were 41 deaths following the clots in Britain, the MHRA said, an increase of 9 from last week's figures, although experts say historic cases might still be feeding through to the totals, and the clots are set to remain a rare event. read more

About 22 million first doses of the AstraZeneca vaccine have been administered in Britain. Four cases of rare clotting were reported following a second dose, but the MHRA did not say how many second doses had been given.

Britain has advised that under-30s receive an alternative to the AstraZeneca-Oxford vaccine, after the MHRA medicine regulator found there was evidence of a link to rare clots with low platelet levels, and officials are considering whether to change advice for people under 40 too. read more

Officials have emphasised the side effect is "vanishingly" rare and advised that most people still get the shots, and AstraZeneca has pointed to regulator recommendations that the vaccine is safe and effective.

Our Standards: The Thomson Reuters Trust Principles.

U.S. lawmakers from both parties and both houses of Congress have introduced eight antitrust bills aimed at tackling the problem of high and rising drug prices, including bills to stop brand name drug companies from paying generic firms to stay off the market.

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.

The industry leader for online information for tax, accounting and finance professionals.

Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface.

Access to real-time, reference, and non-real time data in the cloud to power your enterprise.

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2021 Reuters. All rights reserved

Read full article at Reuters

The Price Action in Many Stocks Is Quite Poor

RealMoney 29 April, 2021 - 09:21am

The most dangerous markets are those that don't go up on good news. There have been some very good earnings reports, the Fed is dovish, we are awash in fiscal stimulus, and the senior indices are hovering at all-time highs, but the price action in many stocks is quite poor.

This morning Facebook (FB) and Apple (AAPL) gapped up on good reports but have traded straight down so far. I would not be surprised to see Apple go red at some point today. The indices are currently around the lows of the day but what is even worse is the continued lack of energy in small-cap stocks. The small names perked up yesterday and have some improved momentum recently, but it is not sustained and fizzles out fast.

There are a few pockets of strength, such as oil, but few themes are attracting interest right now.

It is a peculiar market because, on the surface, it looks quite positive, but if you dig just a little, there is quite a bit of rot. The price action is not reflective of a bull market, but you would not know it from the media coverage

My game plan is to manage positions tightly and not let losses build. I'll also be hunting for some new buys, but I just don't see much. The best names on my screen at the moment are Ocular (OCUL) and Camping World (CWH) .

At the time of publication, James "Rev Shark" DePorre was Long OCUL, CWH.

Thank you, your email to has been sent successfully.

Email Real Money's Wall Street Pros for further analysis and insight

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Business Stories